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Background: It is important to study differential inﬂammatory cellular migration, particularly of eosinophils and
neutrophils, in asthma and how this is inﬂuenced by environmental stimuli such as allergen exposure and the
effects of anti asthma therapy.
Methods:We isolated blood neutrophils and eosinophils from 12 atopic asthmatic human volunteers (Group 1—
four Early Allergic Responders unchallenged (EAR); Group 2 — four Early and Late Allergic Responders (LAR)
challenged; Group 3 — four EAR and LAR challenged and treated with systemic corticosteroids) using cGMP
CD16 CliniMACS. Cells were isolated prior to allergen challenge where applicable, labelled with 99mTc-HMPAO
and then re-infused intravenously. The kinetics of cellular inﬂux/efﬂux into the lungs and other organs were im-
aged via scintigraphy over 4 h, starting at 5 to 6 h following allergen challenge where applicable.
Results: Neutrophils and eosinophils were isolated to a mean (SD) purity of 98.36% (1.09) and 96.31% (3.0), re-
spectively. Asthmatic neutrophils were activated at baseline, mean (SD) CD11bHigh cells 46 (10.50) %. Isolation
and radiolabelling signiﬁcantly increased their activation to N98%. Eosinophils were not activated at baseline,
CD69+ cells 1.9 (0.6) %, increasing to 38 (3.46) % following isolation and labelling. Analysis of the kinetics of
net eosinophil and neutrophil lung inﬂux/efﬂux conformed to a net exponential clearance with respective
mean half times of clearance 6.98 (2.18) and 14.01 (2.63) minutes for Group 1, 6.03 (0.72) and 16.04 (2.0) mi-
nutes for Group2 and 5.63 (1.20) and 14.56 (3.36)minutes for Group3. These did not signiﬁcantly differ between
the three asthma groups (p N 0.05).
Conclusions: Isolation and radiolabelling signiﬁcantly increased activation of eosinophils (CD69) and completely
activated neutrophils (CD11bHigh) in all asthma groups. Net lung neutrophil efﬂux was signiﬁcantly slower than
that of eosinophils in all asthma study groups. There was a trend for pre-treatment with systemic corticosteroids
to reduce lung retention of eosinophils following allergen challenge.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Asthma is a complex, heterogeneous and chronic inﬂammatory lung
disease characterised by reversible bronchoconstriction, airway inﬂam-
mation and hyperresponsiveness (Lemanske and Busse, 2010). Differ-
ential net inﬁltration of effector granulocytes, particularly eosinophilsartment of Imaging Chemistry
gineering, Lambeth Wing, St.
.
. This is an open access article underand neutrophils into the airways forms the basis of current deﬁnitions
of asthma phenotypes and endotypes (Wenzel, 2006; Simpson et al.,
2006).
There remains controversy, however, as to the precisemechanism of
genesis of such phenotypes (Cieslewicz et al., 1999). One of the major
stumbling blocks here is lack of data concerning the kinetics of lung
granulocyte immigration and emigration in asthma. Studies addressing
the differential migration of key effector cells such as eosinophils and
neutrophils have hitherto relied on static, indirect techniques such as
induced sputum, bronchoalveolar lavage and biopsy (Metzger et al.,
1986, 1987). Such strategies do not however address the question ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Incremental allergen challenge.
Sex/Age FEV1 L Pred% EAR% LAR% Allergen
Group 1
EAR
Not challenged
M/44 2.33 69 29 Absent HDM
M/32 4.06 82 20 Absent HDM
F/47 2.13 97 22 Absent Grass
M/61 2.12 66 20 Absent Grass
Group2
EAR & LAR
Challenged
M/25 3.76 83 35 44 Grass
M/24 5.59 105 27 29 HDM
F/21 3.14 82 24 27 Cat
M/28 4.72 119 31 22 HDM
Group 3
EAR & LAR
Challenged/Pretreated
with steroids
F/26 3.21 110 20 20 Cat
M/40 3.04 71 29 34 HDM
M/27 3.93 95 20 36 HDM
M/21 3.69 87 25 18 HDM
HDM—HouseDustMite; FEV1— Forced Expiratory Volume in1 s; Pred%— FEV1percent-
age predicted; EAR — Early Asthmatic Response deﬁned as at least 15% decrease in FEV1
within 30 min following allergen challenge; LAR — Late Asthmatic Response deﬁned as
at least 15% decrease in FEV1 three to 9 h following allergen challenge.
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cells in various compartments of the airways. Furthermore, they do
not inform on the cells that may temporarily marginate in the lungs or
their fate at later time points. Finally, they require artiﬁcial intervention
(sputum induction, BAL)which could be argued and alter the character-
istics of cellular migration in its own right. Thanks to the recent intro-
duction of magnetic bead isolation it has now become possible to
separate pure eosinophils and neutrophils and track their net ingress
and egress in the lungs and other organs in real time, in vivo.
The concept of asthma phenotyping and endotyping is underpinned
partly by the postulated contributions which eosinophils and neutrophils
make to various clinical manifestations of the disease. Disease instability
and airways structural changes are associated with eosinophilic inﬂamma-
tion (Gleich, 2000). Nevertheless, eosinophilic inﬂammation is present only
inabout 50%of asthmatics (Douweset al., 2002), and its presence in clinical
syndromes such as eosinophilic bronchitis does not necessarily lead to
asthma symptoms (Brightling et al., 2003). Equally, neutrophilic inﬂam-
mation is also believed to play a signiﬁcant role in the pathophysiology
of this condition. Activated neutrophils are able to release mediators
that promote and prolong asthma symptoms (Kamath et al., 2005).
The neutrophilic phenotype/endotype has been associated in vari-
ous studies with severe asthma (Little et al., 2002), corticosteroid resis-
tant asthma (Green et al., 2002), nocturnal asthma (Martin et al., 1991),
smokers' asthma (Chalmers et al., 2001), and “sudden onset fatal” asth-
ma (Sur et al., 1993).
We have previously deﬁned the kinetics of net eosinophil and neu-
trophil inﬂux into, and efﬂux from the lungs and other organs of healthy
volunteers by infusing autologous 99mTc-HMPAO radiolabelled puriﬁed
populations of cells followed by gamma camera scanning (Lukawska
et al., 2014). Our aim in this study was to employ the same technique
to examine these kinetics in the lungs of patients with mild/moderate
atopic asthma, further to study the impact of asthma exacerbation and
anti-asthma therapy on this process. To do this we employed the classical
model of bronchial allergen challenge, which induces an immediate or
“early phase reaction” (EAR), characterised by acute bronchoconstriction
maximal around 30 min in suitably sensitised patients and attributed to
the acute release of mediators from mast cells in the airways followed
in some patients after recovery by a second “late phase reaction” (LAR)
characterised by a late period of bronchoconstriction (maximal around
3–9 h) attributed to local release of further mediators including Th2
type cytokines and ongoing cellular inﬁltration. It is not clear why only
a proportion of atopic asthmatics exhibit late phase bronchoconstriction
under these conditions, but this may partly reﬂect individual clinical
sensitivity to allergen challenge, limiting the dosage of allergen which
can be administered to produce a “safe” early response. Both phases are
associated with eosinophil and neutrophil inﬂux into the bronchial
mucosa, but only the late phase reaction, reﬂecting IL-5 and other
mediator release from T cells, is susceptible to corticosteroid inhibition
(O'Byrne et al., 1987). We hypothesised that late phase, allergen-induced
bronchoconstriction in atopic asthmatics, which is known to be associat-
edwith neutrophil and eosinophil inﬂux into the bronchial mucosa, is as-
sociatedwithmodiﬁcation of the kinetics of net eosinophil andneutrophil
inﬂux/efﬂux into and out of the lungs and other organs, and that this is
further modiﬁed in the presence of systemic corticosteroid. To address
this we compared, in real time, the kinetics of this net inﬂux/efﬂux in
lungs, liver, spleen and bone marrow in asthmatics who had previously
demonstrated an isolated EAR in response to allergen challenge, but
were not challenged on this occasion (Group 1), to allergen-challenged
atopic asthmatics who had previously exhibited dual EAR and LAR reac-
tions to allergen and had been re-challenged (Group 2 and Group 3). A
proportion of thepatients (Group3)werepre-administered systemic cor-
ticosteroid. Because of the demanding nature of the protocol it was not
possible to monitor lung function changes concomitantly with gamma
camera imaging. For the same reasonwewere obliged to venesect the pa-
tients for blood eosinophil and neutrophil isolation prior to allergen chal-
lenge.We compared the datawith retrospective, previously reporteddatafrom normal controls obtained using an identical protocol (Lukawska
et al., 2014).
2. Methods
2.1. Clinical Protocol
This studywas approvedby the South East London Ethics Committee
REC 3 and by ARSAC (Administration of Radioactive Substances Adviso-
ry Commitee) as well as the Department of Research and Development
at Guy's and St Thomas' NHS Foundation Trust.
Twelve mild/moderate asthmatics (FEV1 ≥ 65%) were studied on 4
separate occasions (screening, dose-ranging allergen challenge and ei-
ther no further challenge (Group 1) or 2 full dosage allergen challenges
followed by eosinophil and neutrophil tracking on separate occasions).
Asthma was deﬁned as a clinical history of typical symptoms and docu-
mented≥15% variability of the FEV1within the previous 2 years. Atopy
was deﬁned as a positive skin prick test (Aquagen SQ, ALK, Horsholm,
Denmark) to one or more of the challenge aeroallergens (grass pollen,
cat dander, D. pteronyssinus) in the presence of valid positive histamine
and negative saline controls. All asthmatics were treated with inhaled,
short acting bronchodilator only and had been free of exacerbations
and overt upper respiratory tract infections for at least 6 weeks. Their
peripheral blood eosinophil and neutrophil counts were within the
normal laboratory range. All volunteers provided informed, written
consent to participate in the study.
2.2. Incremental Aeroallergen Challenge
This was performed with grass, house dust mite or cat allergen
(Aquagen SQ, ALK, Horsholm, Denmark) according to departmental
Standing Operating Procedure based on well established protocols
(Singh et al., 2007; Ketchell et al., 2002). Volunteers who demonstrated
EAR only following incremental aeroallergen challenge were not chal-
lenged again prior to their gammacamera studies (Group 1). Volunteers
who exhibited both EAR and LAR were challenged with full dose
aeroallergen prior to each subsequent study (Groups 2 and 3) (See
Table 1 for allergen challenge data).
2.3. Full Dosage Aeroallergen Challenge
On two further occasions separated by a minimum period of
28 days, 8 volunteers showing dual responses (EAR and LAR) were re-
challengedwith the same cumulative dosage of allergenwhich had pre-
viously caused these responses but as a single bolus. Theywere split into
Group 2 and Group 3. Volunteers in Group 2 were allergen challenged
with no premedication. Volunteers in Group 3 were premedicated
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day for 5 days prior to challenge. FEV1 was again measured following
a baseline saline challenge and subsequently at 30min intervals follow-
ing bolus allergen challenge, for a total of 10 h. At the end of the exper-
iment, volunteers were administered nebulised salbutamol ad libitum
until FEV1 had improved to at least 90% of the baseline value. The pa-
tient was then issuedwith an action plan and rescuemedication (single
oral dose of prednisolone at 5 mg per kg).
2.4. GMP Neutrophil and Eosinophil Isolation and Radiolabelling
All open manipulations were carried out in a Grade A environment
in a pharmaceutical isolator located in a Grade D background GMP facil-
ity in the Department of Nuclear Medicine at Guy's Hospital, UK. As ex-
plained above, each volunteer in groups 1, 2 and 3 attended on two
separate occasions to undergo reinfusion of eosinophils on one occasion
and neutrophils on the other. Volunteers in Group 2 and 3 underwent
bolus allergen challenge 5 to 6 h prior to reinfusion. Volunteers in
Group 3 on each occasion were pre treated with Prednisolone for ﬁve
days prior to the challenge, but excluding the challenge day. At each
visit the volunteer donated a 110mL sample of venous blood and eosin-
ophils and neutrophils were cGMP isolated using a CliniMACS (Miltenyi
Biotec, Bisley, UK) and radiolabelled with 99mTc-HMPAO (Ceretec, GE
Healthcare, Amersham, UK) as previously described (Lukawska et al.,
2014). Volunteers who underwent bolus allergen challenge (Group 2
and 3) provided their whole blood sample before theywere challenged.
Volunteers in Group 1 were not challenged prior to their scintigraphy
studies.
2.5. Viability, Phenotype and Purity of Puriﬁed Radiolabelled Neutrophils
and Eosinophils
Viability, phenotype, activation and purity of puriﬁed radiolabelled
neutrophils and eosinophils were measured as previously described
(Lukawska et al., 2014).
2.6. Imaging Protocol and Data Analysis
Between 6 and 7 h following peripheral blood sampling, and 5 to 6 h
following allergen challenge where applicable, the volunteer was posi-
tioned in a dual-headed gamma camera (Symbia, Siemens Medical So-
lutions, UK). 100 (96 ± 27) MBq of labelled autologous eosinophils or
neutrophils suspended in 2.5 mL autologous plasma were injected in-
travenously as a bolus. See Lukawska, Livieratos et al. for the full account
of radiolabelling, imaging and data analysis protocols (Lukawska et al.,
2014).
2.7. Statistical Analysis
To test for signiﬁcant differences between the net eosinophil and
neutrophil inﬂux/efﬂux proﬁles in the various organs between the
study groups a Kruskall–Wallis One Way Anova was performed,
with a p value of b0.05 being considered signiﬁcant. If the Kruskal–
Wallis test was signiﬁcant, then a post hoc analysis was performed
by Student–Newman–Keuls pair wise comparison; again p-values
of b0.05 were considered signiﬁcant. The unpaired Student's t test
was used to compare eosinophil and neutrophil activation and num-
bers between the different study groups.
3. Results
3.1. Radiolabelling Efﬁciency
In Group 1 and 2 volunteers, the Tc 99 m HMPAO labelling of eosino-
phils was signiﬁcantly more efﬁcient than that of neutrophils (p= 0.014
and p = 0.01 respectively). In contrast in Group 3 volunteers theefﬁciency of eosinophil labelling was signiﬁcantly (p = 0.0021) reduced
compared to that in Groups 1 and 2, and therewas a trend towards an in-
crease in neutrophil radiolabelling efﬁciency although not signiﬁcant
(p = 0.0537) (Table 2). Overall leukocyte radiolabelling efﬁciencies in
Groups 1 and 2were comparable to those previously published in healthy
subjects (Lukawska et al., 2014).
3.2. Viability, Phenotype and Purity of Puriﬁed Radiolabelled Neutrophils
and Eosinophils
Following the CliniMACS puriﬁcation and radiolabelling procedures
the mean percentage purity of isolated neutrophils, deﬁned as CD66+/
CD16+ cells, exceeded 98%, while the mean percentage purity of eosin-
ophils, deﬁned as CD66+/CD16− cells exceeded 96% (Table 3, Fig. 1).
Importantly the neutrophil fraction contained b0.2% of CD66+/CD16−
eosinophils and b0.15% of mononuclear cells (CD3+, CD19+, CD56+
or CD80+), while the eosinophil fraction contained b0.5% neutro-
phils and b1% mononuclear cells. The mean percentages of activated
CD11bHigh neutrophils in whole blood, as deﬁned in Lukawska et al
were elevated in the asthmatics at baseline compared to healthy vol-
unteerswithmeans of 36% inGroup1, 45% inGroup2 and57% inGroup3,
as compared with ~0.5% previously reported in healthy volunteers
(Lukawska et al., 2014). Following cellular isolation and radiolabelling of
neutrophils the percentages of CD11bHigh cells were further signiﬁcantly
elevated as compared with the ex vivo measurements, to N98% in all 3
groups (Table 3). The mean percentages of activated eosinophils in
whole blood at baseline were 1.9% in Group 1, 3% in Group 2 and 2.5%
in Group 3, comparable to amean of ~1.8% in previously reported healthy
volunteers (Lukawska et al., 2014), suggesting little or no activation of eo-
sinophils prior to isolation. Again, following cellular isolation and
radiolabelling of eosinophils, the percentages of eosinophils expressing
CD69 were signiﬁcantly increased, as compared with untouched eosino-
phils in whole blood, to means of 40% in Group1, 40% in Group 2 and
34% in Group 3 (Table 3). Cellular viability was well maintained in all
groups (Table 3).
3.3. In Vivo Imaging of Neutrophils and Eosinophils
We previously showed that, in healthy individuals, the mean half-
life (t1/2) of net clearance of eosinophils from the lungs differed signiﬁ-
cantly from that of neutrophils, with eosinophils showing much faster
clearance compared with neutrophils (Lukawska et al., 2014). This dif-
ference was maintained and statistically signiﬁcant in all 3 asthma
groups in the present study (Group 1 p = 0.022, Group 2 p = 0.0028,
Group 3 p = 0.005) (Table 4).
There were no signiﬁcant differences in the mean half-times of net
clearance of radiolabelled eosinophils or neutrophils from the lungs of
the asthmatics previously demonstrating an isolated EAR but not chal-
lenged (Group 1), and asthmatics with EAR and LAR whowere allergen
challenged without (Group 2) or with (Group 3) pre-treatment with
corticosteroid (p N 0.05) (Fig. 2, Table 4). Retrospective comparison of
these kineticswith those in healthy volunteers using an identical protocol
(Lukawska et al., 2014) suggested that the half time of clearance of eosin-
ophils from the lungs of the unchallenged asthmatics (Group 1) was sig-
niﬁcantly higher compared with normal controls (p = 0.0428).
Combined time activity curves for eosinophil and neutrophil mean
counts over the lungs, liver and spleen are shown in Fig. 2. There were
no signiﬁcant differences in net eosinophil migration into and out of
the spleen between the three asthma groups. There was also no signiﬁ-
cant difference between the asthma groups and previously published
kinetic data from normal volunteers (Lukawska et al., 2014). Further
comparison with these retrospective data showed that signiﬁcantly
fewer neutrophils were retained in the spleen at 1 h in corticosteroid
pre-treated asthmatics (Group 3) compared to healthy volunteers
(p = 0.012). Signiﬁcantly fewer eosinophils were retained in the liver
at 1 h in the corticosteroid pre-treated volunteers (Group 3) when
Table 2
Mean radiolabelling efﬁciencies of eosinophils and neutrophils in the 3 asthmatic study groups. Standard deviations given in brackets. Radiolabelling efﬁciencywasmeasured by dividing
the activity of the neutrophil/eosinophil pellet (in MBq) by the total activity (pellet and supernatant) × 100% following 99mTc-HMPAO incubation.
Mean radiolabelling efﬁciency (%) Group 1
EAR not challenged
Group 2
EAR & LAR challenged
Group 3
EAR & LAR challenged & pre-treated steroids
Eosinophil 80.18 (3.32) 69.18 (7.1) 46.58 (17.82)
Neutrophils 38.87 (6.28) 24.80 (4.57) 54.68 (17.01)
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phils than neutrophils were retained in the bone marrow at 4 h
(p = 0.0287) in all asthma study groups. This was consistent with
the data from healthy volunteers (Lukawska et al., 2014).
3.4. Safety and Tolerability
In order to be repeatable, for example to study potential changes in
leukocyte migration following therapy or over time, the procedure
must be tolerable. In terms of exposure to radiation, we used less than
half the dose per imaging study than is typically used for a clinical
white blood cell scan. So, in principle this could be used for repeated ex-
aminations. Our volunteers were required to lie ﬂat and still in the scan-
ner for periods of up to 30 min, some of them while experiencing late
phase bronchoconstriction following the allergen challenge. In practice,
all of our volunteers tolerated this as well as can be expected on two
separate occasions and, at least informally, reported that they would
be prepared to undergo repeated examinations in the future.
4. Discussion
Recently we validated the technique of cGMP isolation of eosino-
phils and neutrophils from peripheral blood of normal volunteers,
radiolabelling and re-infusing themand then using gamma scintigraphy
to track theirmigration. The resulting accumulation and decay of the ra-
dioactivity in entire body organs, which reﬂects the time course of net
inﬂux and efﬂux of these cells into and out of the target organs was re-
ported (Lukawska et al., 2014).We found that the decay of net retention
of pure eosinophils and neutrophils in the lungs conformed to a single
exponential model time activity curve, and that the mean half time of
lung net clearance of eosinophils was signiﬁcantly reduced compared
with that of neutrophils.
In the present studywe have utilised this technique in an attempt to
track perturbations in net differential inﬂux/efﬂux of eosinophils andTable 3
In vitro characterisation of puriﬁed human neutrophils and eosinophils.
Group 1
EAR not
challenged
Group 2
EAR & LAR
challenged
Group 3
EAR & LAR challenged &
pre-treated steroids
Neutrophils (CD66+, CD16+a)
Purityb (%) 98.5 (±1.1) 98.3 (±1.5) 98.2 (±0.9)
% CD11b+ ex vivo
whole blood
35.7 (±13.7) 44.6 (±34.4) 56.8 (±44.0)
% CD11b+ after
radiolabelling
99.8 (±0.2) 98 (±1.8) 99.2 (±0.5)
Viability (%) 97.0 (±3.3) 98.2 (±3.2) 92.7 (±2.3)
Eosinophils (CD66+, CD16−a)
Purityb (%) 96.1 (±4.2) 96.5 (±2.4) 96.4 (±3.5)
% CD69+ ex vivo
whole blood
1.9 (±1.0) 3.0 (±2.1) 2.5 (±2.7)
% CD69+ after
radiolabelling
39.6 (±25.2) 39.7 (±28.1) 33.7 (±27.0)
Viability (%) 96.0 (±4.0) 95.5 (2.08) 93.4 (±3.8)
a Phenotype following CD16 CliniMACS isolation.
b Contaminants were deﬁned as CD3, CD19, CD56 or CD80 positive mononuclear cells
and eosinophils (CD66+/CD16− cells) in the neutrophil fraction and mononuclear cells
and neutrophils (CD66+/CD16+ cells) in the eosinophil fraction. Figures represent
mean ± SD.neutrophils from the lungs and other organs during the course of the
late phase bronchoconstrictor response to allergen challenge of atopic
asthmatics showing both EAR and LAR (Groups 2 and 3), some of
whom were pretreated with systemic corticosteroids (Group 3), and
comparing with asthmatics previously displaying an isolated EAR who
were not challenged (Group 1). Each volunteer was imaged on two
separate occasions. We were able to conﬁrm our previous ﬁndings in
non-diseased controls that the kinetics of net inﬂux/efﬂux of eosino-
phils and neutrophils into and out of the lungs are fundamentally differ-
ent (Lukawska et al., 2014). Comparison of these kinetics with our
previously reported data in normal controls using an identical tech-
nique also revealed a signiﬁcantly elevated half time of retention of eo-
sinophils in the lungs of the unchallenged asthmatics (t1/2 = 6.98)
compared with the normal controls (t1/2 = 4.16).
We hypothesised that we would be able to observe signiﬁcant pro-
longation of t1/2 of the net kinetics of eosinophil inﬂux/efﬂux in the
lungs of allergen challenged asthmatics during the peak of the late-
phase asthmatic response when compared to unchallenged stable asth-
matics, and that these kinetics would be further modiﬁed in the pres-
ence of systemic corticosteroid, which is known to attenuate this late
response. In this studywewere unable to do so, butwe did however ob-
serve the following trends. It was notable that systemic corticosteroid
therapy was associated with a trend for faster clearance of eosinophils
from the lungs of the treated asthmatics, with rates (t1/2 of 5.63)
approaching those previously observed in non-diseased healthy indi-
viduals (t1/2 of 4.16) (Lukawska et al., 2014). There was a trend for re-
tention of eosinophils in the lungs of challenged volunteers (Group
2) (t1/2 = 6.03) compared to asthmatics recently treated with cortico-
steroids and healthy volunteers. There was no similar trend observed
in neutrophil studies of the same groups of subjects.
What we found interesting was the increased t1/2 of eosinophil lung
retention in Group 1 patients (EAR, no challenge) when compared to
healthy volunteers, but the lack of evidence of any such effect in allergen
challenged volunteers in Groups 2 and 3. This we expected to be
greatest in Group 2. We propose several possible explanations for this.
Firstly, as this study involved the use of radioactive tracer and a de-
manding protocol, our volunteer numbers in each study group were
modest (4 participants). It is possible therefore that the study was un-
derpowered statistically, although this in turn implies that any differ-
ences, had they existed, must have been very subtle. Secondly, and we
believe possibly most importantly, the data from patients in Groups 2
and 3mayhave been confounded by our inability tomaintain haemody-
namic stability. Since our protocol for patients in Groups 2 and 3 in-
volved their lying ﬂat and immobile in the scanner during the phase
of considerable bronchoconstriction associatedwith the LAR this almost
certainly induced sinus tachycardia (British Thoracic Society/Scottish
Intercollegiate Guidelines Network, 2003), which in turn may have re-
sulted in increased blood ﬂow through the pulmonary circulation, dilut-
ing any tendency for eosinophil retention introduced by the allergen
challenge. Thirdly, it is also possible that measurements made in this
relatively low resolution scanning technique may have been confound-
ed by changes in the ventilation/perfusion dynamics in allergen chal-
lenged asthmatic airways: there exists evidence that, during asthmatic
bronchoconstriction defects in ventilation are spatially associated with
defects in perfusion (i.e. hypoventilated regions are also hypoperfused)
(Harris et al., 2006). This may arise from mechanical compression of
blood vessels of the pulmonary circulation and/or effects of local hypoxia,
A B
C D
Fig. 1. Blood neutrophils and eosinophils following CliniMACS separation (magniﬁcation ×40). A) Pure neutrophils from an asthmatic subject. B) Pure eosinophils from an asthmatic sub-
ject. C) Pure neutrophils from an asthmatic subject following corticosteroid pre-treatment. D) Pure eosinophils from an asthmatic subject following corticosteroid pre-treatment.
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hypoxic pulmonary vasoconstriction (HPV). HPV is believed to be an
adaptive mechanism unique to the pulmonary circulation that allows
redirection of blood ﬂow to alveoli with higher oxygen tension, thereby
reducing ventilation/perfusion mismatch (Hunter et al., 2004). Conse-
quently blood ﬂow in the pulmonary circulation in these experiments
may have been diverted away from regions most affected by allergen
challenge, which would again tend to dilute any measured effect on the
migration of blood cells such as eosinophils and neutrophils.
In future studies involving allergen challenge,we plan to scan patients
in an upright sitting position. This we believe will improve their haemo-
dynamic stability, HPV and overall comfort during the investigation.
Finally, there are someother caveats to be considered. Because of the
time required to purify and radiolabel blood eosinophils and neutro-
phils ex vivo it was logistically impossible to reinfuse the labelled cells
earlier than 5–6 h after blood sampling. Full processing and labelling
of reinfused cells prior to commencing challenge would have required
a 24 h protocol. Consequently we timed our scans to coincide with the
period during the peak of LAR, commencing 6 h after allergen challenge,
but wewere unable to gather any data earlier than this. It is conceivable
that precise timing of the scans may be critical here: there is some
evidence, for example, that neutrophil inﬂux into allergen-challenged
airways is early and transient (Koh et al., 1993; Kelly et al., 2000;
Nocker et al., 1999). For the same reason, the whole blood used for
neutrophil/eosinophil isolation from the subjects was obtained just
prior to, rather than after allergen challenge. It is possible that the chal-
lenge procedure itselfmight have altered the functions of populations of
circulating eosinophils and neutrophils available for labelling. In design-
ing future studies of real time tracking of net granulocyte inﬂux andTable 4
Mean half times T1/2 of clearance (minutes) of eosinophils and neutrophils from the lungs of v
Lung T (1/2) Group 1
EAR not challenged
Group
EAR &
Eosinophil 6.98 (2.18) 6.03
Neutrophils 14.01 (2.63) 16.04efﬂux from the lungs of asthmatics, and especially those involving aller-
gen challenge or other forms of induced bronchoconstriction, these con-
siderations must be taken into account.
As a readout of neutrophil activation, both ex vivo and following the
isolation procedure, we monitored the percentages of these cells ex-
pressingCD11b (CD11bHigh) above a predeterminedﬂuorescence inten-
sity. We chose CD11b because it is an integrin component implicated in
cellular adhesion, leukoaggregation and pulmonary sequestration of
granulocytes although neutrophil migration, as distinct from adhesion
more clearly depends on co-expression of CD18 in the integrin hetero-
dimer (Vedder and Harlan, 1988). What we found was that the mean
percentages of blood neutrophils expressing CD11b above this thresh-
old directly ex vivowere already elevated in the three groups of patients
with asthma (to 36% in Group 1, 45% in Group 2 and 57% in Group 3) as
compared (retrospectively (Lukawska et al., 2014))with healthy volun-
teers (~0.5%) even following isolation. This is likely to reﬂect priming by
underlying chronic inﬂammation (Mann and Chung, 2006; Kämpe et al.,
2011). Following the isolation and radiolabelling processes, these in-
creased further to N98% in all three groups of asthmatics. Nevertheless,
this had no signiﬁcant effect, within the resolution of our measure-
ments, on the net kinetics of inﬂux and efﬂux of these cells into and
out of the lungs, not only in the patients with asthma but also (retro-
spectively (Lukawska et al., 2014)) in the healthy volunteers: when
we compared the kinetics of net lung neutrophil inﬂux/efﬂux in
healthy volunteers (CD11bHigh 1.1 ± 0.8%) and all three asthma
groups (CD11bHigh N98%) we uncovered no signiﬁcant differences.
Similarly, as a readout of eosinophil activationwemonitored the per-
centages of these cells expressing CD69. CD69 is an activation marker
on subgroups of T cells as well as eosinophils, and has also beenolunteers in 3 asthma study groups. Standard deviations shown in brackets.
2
LAR challenged
Group 3
EAR & LAR challenged & pretreated steroids
(0.72) 5.63 (1.20)
(2.00) 14.56 (3.36)
178 J.J. Lukawska et al. / EBioMedicine 1 (2014) 173–180implicated in delaying the egress of T cells from lymph nodes (Zhi et al.,
2011). In this case we found that the mean percentages of eosinophils
expressing CD69were not signiﬁcantly different in the 3 groups of asth-
matic patients (1.9% in Group 1, 3% in Group 2 and 2.5% in Group 3) and
retrospectively (Lukawska et al., 2014) in healthy volunteers (~1.8%)
directly ex vivo, while the process of isolation and radiolabelling signif-
icantly increased the mean percentages of eosinophils expressing CD69
in all 3 groups of asthmatic patients (to 40% in Group 1, 40% in Group 2
and 34% in Group 3) but not healthy volunteers (~4.8%). One could
speculate that this might have been higher still if the procedures had
been performed in the asthmatics following allergen challenge. As
with neutrophils, this had no signiﬁcant effect, within the resolution
of our measurements, on the net kinetics of inﬂux and efﬂux of these
cells into and out of the lungs in the asthmatic patients. The only signif-
icant differencewewere able to observe (retrospectively) was a greater
net retention time of eosinophils in the Group 1 asthmatic patients as
compared with the healthy volunteers. Consequently, although it is ap-
propriate to be concerned about the possible effects of cellular isolation
and labelling on cellular functions and properties in vivo, and although
we chose what we perceived as likely relevant functional markers,
expression of neither CD11b on neutrophils nor CD69 on eosinophils
appeared to alter their migration kinetics in this study. The factors
which governnet cellularmigration into andout of organs in vivo are like-
ly highly complex and variable, and as yet relatively poorly understood,
and in time it may be possible to identify more appropriate markers to
“screen” for possible effects of cellular isolation on these processes. We0
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Fig. 2. A. Eosinophil organ speciﬁc asthma time activity curves for: lung, liver, spleen. Error ba
curves for: lung, liver, spleen. Error bars represent ± one standard deviation.do not believe, however, that this reservation detracts from the intrinsic
value of our observations and of the process, and indeed further experi-
ments may result in more appropriate markers of “activation”which in-
ﬂuence cellular migration to be deﬁned.
As previously reported, the radiolabelling data indicated that eosin-
ophils radiolabel with 99mTc-HMPAO with a far higher speciﬁc activity
(10 to 25 times higher) than neutrophils and thus are likely to contrib-
ute to more than 50% of the signal in unseparated granulocyte popula-
tions in vivo (Lukawska et al., 2014). It was notable in the present
study that prior corticosteroid therapy of the asthmatics reduced the
radiolabelling efﬁciency of pure eosinophils (p = 0.002) and tended to
increase that of neutrophils, although not signiﬁcantly (p = 0.0537).
This likely results from the mechanism by which 99mTc-HMPAO is nor-
mally preferentially taken into the small secretory vesicles of eosinophils
and less so into the vesicles of neutrophils (Moberg et al., 2001). We
hypothesise that the numbers of secretory vesicles in corticosteroid pre-
treated eosinophils are diminished, resulting in poorer radiolabelling efﬁ-
ciency. This would have an impact on scanning data frommixed granulo-
cyte populations, but should not affect a pure eosinophil or neutrophil
scan.
In conclusion, we have demonstrated that differential, in vivo real
time tracking of eosinophil and neutrophil migration into the lungs is
feasible in asthmatics, even following experimental allergen challenge,
as well as healthy volunteers. Given the complexity of the procedures
involved in this work, it might be more appropriately regarded as a
proof of concept study (the concept that asthmatics can be challenged,150 200 250
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179J.J. Lukawska et al. / EBioMedicine 1 (2014) 173–180reinfusedwith labelled granulocytes and scannedwithin the time frame
of the late phase reaction) than a deﬁnitely statistically powered inves-
tigation. While we failed to demonstrate differences between eosinophil
or neutrophil efﬂux/inﬂux in the three asthma groups using the current
protocol, we have identiﬁed a number of critical issues that, with modiﬁ-
cation of the protocol and treatment of bronchoconstriction in challenged
individuals should allowus to develop the technique as a key tool for phe-
notyping asthma and as an in vivo biomarker for the directing of novel
asthma therapies. Data from this study are being used to determine suit-
able sample sizes required to power a Phase 1/2 clinical study.
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